ACST - Acasti Pharma issues clarification on trading activity
After surging +72.0% during the day, the nano-cap Acasti Pharma (ACST) has added another +3.9% in the after-hours market.With trading volumes soaring, the company’s management and the board of directors confirm they are unaware of any material change in the company’s operations resulting in the unusual increase in trading.Having failed in two Phase 3 trials, the company will not file an NDA for its lead product candidate CaPre®, Acasti announced in November.It has engaged Oppenheimer for a strategic review of the business with alternatives, including a merger, business combination, or other strategic transaction on the table.
For further details see:
Acasti Pharma issues clarification on trading activity